BioSpace News Archive

HCP, Inc. announced today that it has agreed to sell 15,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 13,000,000 shares offered on a forward basis in connection with the forward sale agreement described below, at a price of $28.90 per share (before deducting underwriting discounts and commissions).

Assistance for UnitedHealthcare plan participants whose access to care or prescriptions needs may have been affected

Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares.

Organogenesis Holdings Inc. today announced the completion of its previously announced business combination between Organogenesis Inc. and Avista Healthcare Public Acquisition Corp. (“AHPAC”).

HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest.

Bryce Williams, president & CEO of HealthMine, Inc., the Health Action as a Service company (HAaaS), will be presenting at the 9th Annual RISE Star Ratings Master Class. Williams will present on “Improving star quality ratings: how to think like a start-up to drive clinical health action,” on Wednesday, December 12th from 11:00 AM - 11:25 AM at the Fairmont Grand Del Mar Hotel in San Diego, California.

Mr. O’Day Brings Global Pharmaceutical Leadership Experience Across Geographies and Therapeutic Areas

Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.

Dr. Tse’s Extensive Track Record in Oncology Early Clinical Development Will Strengthen CStone’s Core Competence as a Clinical Development Engine and Solidify CStone’s Position Among Leading Innovative Biopharma Companies in China

CertainT provides physical identity and authentication to assets tracked through complex supply chains on the Everledger platform